

Name Of The Company PHARMAIDS PHARMACEUTICALS LIMITED

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31st March,2018

Particulars	QUARTER ENDED			YEAR ENDED	
	31.03.2018	31.12.2017	31.03.2017	31.03.2018	31.03.2017
	Unaudited	Audited	Unaudited	Audited	Audited
Income					
Revenue from Operations	3.11	17.32	25.79	44.91	120.25
Other Income	1.20	0.41	0.97	2.01	1.01
Total Income	4.31	17.73	26.76	46.92	121.26
Expenses					
Cost of Material Consumed	0.80	0.00	(5.81)	3.47	64.49
Purchase of Stock in Trade	1.03	16.03	20.69	24.19	0.00
Changes in Inventory of Finished Goods, Work in Progress and Stock in Trade	1.05	0.06	2.48	21.78	2.95
Employee benefit expenses	0.02	1.14	1.91	6.30	16.63
Finance Cost	0.06	0.03	0.05	0.14	4.01
Depreciation and amortisation expense	0.07	0.02	0.49	0.11	6.37
Other expenses	4.30	8.63	41.84	27.79	70.53
Total expenses	7.33	25.91	61.65	83.78	164.98
Profit/ (loss) before exceptional items and tax	(3.02)	(8.18)	(34.89)	(36.86)	(43.72)
Exceptional items	0.00	0.00	51.97	0.00	51.97
Profit/ (loss) before tax	(3.02)	(8.18)	17.08	(36.86)	8.25
Tax expenses	0.00	0.00	0.00	0.00	0.00
(1)Current Tax	(0.02)	0.00	0.00	1.73	0.00
(2) Differed Tax	(0.02)	0.00	(2.72)	(0.02)	(2.72)
Profit/ (loss) for the period from continuing operations	(2.98)	(8.18)	19.80	(38.57)	10.97
Profit/ (loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00
Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
Profit/ (loss) from discounting operations (after tax)	0.00	0.00	0.00	0.00	0.00
Profit/ (loss) for the period	(2.98)	(8.18)	19.80	(38.57)	10.97
Other comprehensive income	0.00	0.00	0.00	0.00	0.00
Total comprehensive income for the period	0.00	0.00	0.00	0.00	0.00
(Profit/ loss + other comprehensive income)	0.00	0.00	0.00	0.00	0.00
Earnings per equity share (for continuing operations)					
a) Basic	(0.09)	(0.24)	0.50	(1.13)	0.32
b) Diluted	(0.09)	(0.24)	0.50	(1.13)	0.32
Earnings per equity share (for discontinued operations)					
a) Basic	0.00	0.00	0.00	0.00	0.00
b) Diluted	0.00	0.00	0.00	0.00	0.00
Earnings per equity share (for discontinued & continuing operations)					
a) Basic	(0.09)	(0.24)	0.50	(1.13)	0.32
b) Diluted	(0.09)	(0.24)	0.50	(1.13)	0.32

NOTES: 1. These results were approved at the meeting of the Board of Directors held on May 29,2018. 2. The Company operates in a single segment 3. As required under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation,2015, the Limited Review by the Statutory Auditors has been completed and the Unmodified Report forwarded to BSE Ltd. The said Report does not have any impact on the above results and Notes which needs explanation. 4. Figures for the previous periods have been regrouped, wherever necessary, to correspond with the current period.





RAKESH S JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS

B. Ramesh Kumar (Mob) : +91-9849025641
E-mail : rsjainassociates@rediffmail.com

14-6-191, Nagar Khana, Begum Bazar,
Hyderabad - 500 012. (T.S.) INDIA.

Date :

Auditor's Report On Quarterly Financial Results and Year to Date Results of M/s Pharmaids Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015

To
Board of Directors
M/s Pharmaids Pharmaceuticals Limited
Hyderabad

We have audited the quarterly financial results of **M/s Pharmaids Pharmaceuticals Limited** for the quarter ended **31st March 2018** and the year to date results for the period **01st April 2017 to 31st March 2018** attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly standalone financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the loss and other financial information for the quarter ended 31st March, 2018 as well as the year to date results for the period from 01st April 2017 to 31st March 2018

For **RAKESH S JAIN & ASSOCIATES**
Chartered Accountants
Firm Registration no.:0101295



B. Ramesh Kumar
(B. Ramesh Kumar)
Partner
M.No: 200304

Place: Hyderabad
Date: 05/05/2018